High Hurdle For Novartis's New Oncology Division

Novartis AG has nailed its oncology colors firmly to the mast by restructuring its pharmaceuticals division to separate out cancer from the rest of its pharma business. But the changes do not disguise the need to offset the loss of patent protection for its pioneering targeted anticancer blockbuster Gleevec (imatinib).